|
|
Prepublished online as a Blood First Edition Paper on March 6, 2003; DOI 10.1182/blood-2002-12-3718.
 Previous Article | Table of Contents | Next Article 
Blood, 1 July 2003, Vol. 102, No. 1, pp. 269-275
NEOPLASIA
Regulation of 17-AAG—induced apoptosis: role of Bcl-2, Bcl-xL, and Bax downstream of 17-AAG—mediated down-regulation of Akt, Raf-1, and Src kinases
Ramadevi Nimmanapalli,
Erica O'Bryan,
Deborah Kuhn,
Hirohito Yamaguchi,
Hong-Gang Wang, and
Kapil N. Bhalla
From the Department of Interdisciplinary Oncology, University of South Florida, Moffitt Cancer Center and Research Institute, Tampa, FL.
17-allylamino-demethoxy geldanamycin (17-AAG) inhibits the chaperone function of heat shock protein—90 (Hsp-90) and promotes the proteasomal degradation of its misfolded client proteins. Here, we demonstrate that treatment of the human acute myeloid leukemia HL-60 cells with 17-AAG attenuates the intracellular levels of a number of Hsp-90 client proteins, including Akt, c-Raf-1, and c-Src. Also, 17-AAG induced the mitochondrial release and cytosolic accumulation of cytochrome c (cyt c) and second mitochondria-derived activator of caspases (Smac)/DIABLO, resulting in the activation of caspase-9 and caspase-3 and apoptosis. Treatment with 17-AAG triggered the B-cell lymphoma—2 (Bcl-2)—associated X protein (Bax) conformational change associated with apoptosis, while Bax-deficient cells were resistant to 17-AAG—induced apoptosis. In addition, in HL-60/Bcl-2 and HL-60/Bcl-xL cells, which ectopically express Bcl-2 and Bcl-xL respectively, 17-AAG—induced Bax conformational change, cytosolic accumulation of cyt c and Smac/DIABLO, and apoptosis were markedly inhibited. Although the rate of 17-AAG—mediated decline in Akt, c-Raf-1, and c-Src levels was blunted, the total decline was not compromised in HL-60/Bcl-2 and HL-60/Bcl-xL cells. Cotreatment with HA14-1, a nonpeptidic ligand that can bind and inhibit the antiapoptotic activity of Bcl-2, significantly overcame the resistance to 17-AAG—induced apoptosis in HL-60/Bcl-2 cells. Together, these findings indicate that although 17-AAG treatment causes the levels of a number of survival-signaling protein kinases to decline, the downstream engagement of the mitochondrial pathway of apoptosis is regulated by the activity of the Bcl-2 family of proteins. Also, neutralizing the antiapoptotic effect of Bcl-2 would further enhance the antileukemia activity of 17-AAG. (Blood. 2003;102:269-275)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. K. Wandinger, K. Richter, and J. Buchner
The Hsp90 Chaperone Machinery
J. Biol. Chem.,
July 4, 2008;
283(27):
18473 - 18477.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Mitchell, M. A. Park, G. Zhang, S. I. Han, H. Harada, R. A. Franklin, A. Yacoub, P.-L. Li, P. B. Hylemon, S. Grant, et al.
17-Allylamino-17-demethoxygeldanamycin enhances the lethality of deoxycholic acid in primary rodent hepatocytes and established cell lines
Mol. Cancer Ther.,
February 1, 2007;
6(2):
618 - 632.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. V Powers and P. Workman
Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors
Endocr. Relat. Cancer,
December 1, 2006;
13(Supplement_1):
S125 - S135.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. K. McCollum, C. J. TenEyck, B. M. Sauer, D. O. Toft, and C. Erlichman
Up-regulation of Heat Shock Protein 27 Induces Resistance to 17-Allylamino-Demethoxygeldanamycin through a Glutathione-Mediated Mechanism.
Cancer Res.,
November 15, 2006;
66(22):
10967 - 10975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Gyurkocza, J. Plescia, C. M. Raskett, D. S. Garlick, P. A. Lowry, B. Z. Carter, M. Andreeff, M. Meli, G. Colombo, and D. C. Altieri
Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors.
J Natl Cancer Inst,
August 2, 2006;
98(15):
1068 - 1077.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Fiskus, M. Pranpat, P. Bali, M. Balasis, S. Kumaraswamy, S. Boyapalle, K. Rocha, J. Wu, F. Giles, P. W. Manley, et al.
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells
Blood,
July 15, 2006;
108(2):
645 - 652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Rzepecki, T. Sarosiek, and C. Szczylik
Alemtuzumab, Fludarabine and Melphalan as a Conditioning Therapy in Severe Aplastic Anemia and Hypoplastic Myelodysplastic Syndrome--Single Center Experience
Jpn. J. Clin. Oncol.,
January 1, 2006;
36(1):
46 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Guo, K. Rocha, P. Bali, M. Pranpat, W. Fiskus, S. Boyapalle, S. Kumaraswamy, M. Balasis, B. Greedy, E. S. M. Armitage, et al.
Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin
Cancer Res.,
November 15, 2005;
65(22):
10536 - 10544.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bali, M. Pranpat, R. Swaby, W. Fiskus, H. Yamaguchi, M. Balasis, K. Rocha, H.-G. Wang, V. Richon, and K. Bhalla
Activity of Suberoylanilide Hydroxamic Acid Against Human Breast Cancer Cells with Amplification of Her-2
Clin. Cancer Res.,
September 1, 2005;
11(17):
6382 - 6389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. A. Mesa, D. Loegering, H. L. Powell, K. Flatten, S. J. H. Arlander, N. T. Dai, M. P. Heldebrant, B. T. Vroman, B. D. Smith, J. E. Karp, et al.
Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine
Blood,
July 1, 2005;
106(1):
318 - 327.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Rahmani, E. Reese, Y. Dai, C. Bauer, L. B. Kramer, M. Huang, R. Jove, P. Dent, and S. Grant
Cotreatment with Suberanoylanilide Hydroxamic Acid and 17-Allylamino 17-demethoxygeldanamycin Synergistically Induces Apoptosis in Bcr-Abl+ Cells Sensitive and Resistant to STI571 (Imatinib Mesylate) in Association with Down-Regulation of Bcr-Abl, Abrogation of Signal Transducer and Activator of Transcription 5 Activity, and Bax Conformational Change
Mol. Pharmacol.,
April 1, 2005;
67(4):
1166 - 1176.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. George, P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja, et al.
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
Blood,
February 15, 2005;
105(4):
1768 - 1776.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Takagaki, S. Katsuma, Y. Kaminishi, T. Horio, T. Tanaka, T. Ohgi, and J. Yano
Role of Chk1 and Chk2 in Ara-C-induced differentiation of human leukemia K562 cells
Genes Cells,
February 1, 2005;
10(2):
97 - 106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Beere
`The stress of dying': the role of heat shock proteins in the regulation of apoptosis
J. Cell Sci.,
June 1, 2004;
117(13):
2641 - 2651.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. George, P. Bali, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, W. Fiskus, A. Scuto, S. Annavarapu, et al.
Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3
Cancer Res.,
May 15, 2004;
64(10):
3645 - 3652.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
